^
Association details:
| Biomarker: | Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
Published date:
02/08/2022
Excerpt:
Case 1 is a 33-year-old female diagnosed with AML...t(8;21)(q22;q22) (8)/46, XX, idem (2), AML1-ETO was 39700 copies/10000 abl copies (AML1-ETO transcripts were normalized to 104 abl copies), and KIT exon 17 and CSF3R mutations were detected....Then, one cycle of venetoclax+midostaurin chemotherapy (venetoclax 100 mg qd d1-21, midostaurin 50 mg bid d1-21) was administered...venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
DOI:
https://doi.org/10.3389/fonc.2022.841276
